These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 8717400)

  • 1. Bacterial ghosts: non-living candidate vaccines.
    Szostak MP; Hensel A; Eko FO; Klein R; Auer T; Mader H; Haslberger A; Bunka S; Wanner G; Lubitz W
    J Biotechnol; 1996 Jan; 44(1-3):161-70. PubMed ID: 8717400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacterial ghosts as multifunctional vaccine particles.
    Szostak MP; Mader H; Truppe M; Kamal M; Eko FO; Huter V; Marchart J; Jechlinger W; Haidinger W; Brand E; Denner E; Resch S; Dehlin E; Katinger A; Kuen B; Haslberger A; Hensel A; Lubitz W
    Behring Inst Mitt; 1997 Feb; (98):191-6. PubMed ID: 9382740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery.
    Jalava K; Eko FO; Riedmann E; Lubitz W
    Expert Rev Vaccines; 2003 Feb; 2(1):45-51. PubMed ID: 12901596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended recombinant bacterial ghost system.
    Lubitz W; Witte A; Eko FO; Kamal M; Jechlinger W; Brand E; Marchart J; Haidinger W; Huter V; Felnerova D; Stralis-Alves N; Lechleitner S; Melzer H; Szostak MP; Resch S; Mader H; Kuen B; Mayr B; Mayrhofer P; Geretschläger R; Haslberger A; Hensel A
    J Biotechnol; 1999 Aug; 73(2-3):261-73. PubMed ID: 10486935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New strategies for combination vaccines based on the extended recombinant bacterial ghost system.
    Eko FO; Witte A; Huter V; Kuen B; Fürst-Ladani S; Haslberger A; Katinger A; Hensel A; Szostak MP; Resch S; Mader H; Raza P; Brand E; Marchart J; Jechlinger W; Haidinger W; Lubitz W
    Vaccine; 1999 Mar; 17(13-14):1643-9. PubMed ID: 10194817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors.
    Walcher P; Mayr UB; Azimpour-Tabrizi C; Eko FO; Jechlinger W; Mayrhofer P; Alefantis T; Mujer CV; DelVecchio VG; Lubitz W
    Expert Rev Vaccines; 2004 Dec; 3(6):681-91. PubMed ID: 15606353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Generation of Aeromonas hydrophila ghosts and their evaluation as oral vaccine candidates in Carassius auratus gibelio].
    Chu W; Zhuang X; Lu C
    Wei Sheng Wu Xue Bao; 2008 Feb; 48(2):202-6. PubMed ID: 18438002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterial ghosts as adjuvant particles.
    Riedmann EM; Kyd JM; Cripps AW; Lubitz W
    Expert Rev Vaccines; 2007 Apr; 6(2):241-53. PubMed ID: 17408373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of Vibrio cholerae ghosts (VCG) by expression of a cloned phage lysis gene: potential for vaccine development.
    Eko FO; Szostak MP; Wanner G; Lubitz W
    Vaccine; 1994 Oct; 12(13):1231-7. PubMed ID: 7530888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Green fluorescent protein (GFP)-dependent separation of bacterial ghosts from intact cells by FACS.
    Haidinger W; Szostak MP; Beisker W; Lubitz W
    Cytometry; 2001 Jun; 44(2):106-12. PubMed ID: 11378860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fish vaccine antigens produced or delivered by recombinant DNA technologies.
    Leong JC; Anderson E; Bootland LM; Chiou PW; Johnson M; Kim C; Mourich D; Trobridge G
    Dev Biol Stand; 1997; 90():267-77. PubMed ID: 9270855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial ghosts as antigen delivery vehicles.
    Mayr UB; Walcher P; Azimpour C; Riedmann E; Haller C; Lubitz W
    Adv Drug Deliv Rev; 2005 Jun; 57(9):1381-91. PubMed ID: 15878634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial ghosts as a delivery system for zona pellucida-2 fertility control vaccines for brushtail possums (Trichosurus vulpecula).
    Walcher P; Cui X; Arrow JA; Scobie S; Molinia FC; Cowan PE; Lubitz W; Duckworth JA
    Vaccine; 2008 Dec; 26(52):6832-8. PubMed ID: 18948157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mice orally vaccinated with Edwardsiella tarda ghosts are significantly protected against infection.
    Wang X; Lu C
    Vaccine; 2009 Mar; 27(10):1571-8. PubMed ID: 19166892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial ghosts as vaccine candidates for veterinary applications.
    Jalava K; Hensel A; Szostak M; Resch S; Lubitz W
    J Control Release; 2002 Dec; 85(1-3):17-25. PubMed ID: 12480307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal immunization using recombinant plant-based oral vaccines.
    Streatfield SJ
    Methods; 2006 Feb; 38(2):150-7. PubMed ID: 16431131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell-specific immune response induced by bacterial ghosts.
    Felnerova D; Kudela P; Bizik J; Haslberger A; Hensel A; Saalmuller A; Lubitz W
    Med Sci Monit; 2004 Oct; 10(10):BR362-70. PubMed ID: 15448589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a tripartite vector system for live oral immunization using a gram-negative probiotic carrier.
    Buddenborg C; Daudel D; Liebrecht S; Greune L; Humberg V; Schmidt MA
    Int J Med Microbiol; 2008 Jan; 298(1-2):105-14. PubMed ID: 17936683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of non-toxic Escherichia coli and Vibrio cholerae strains expressing high and immunogenic levels of enterotoxigenic E. coli colonization factor I fimbriae.
    Tobias J; Lebens M; Bölin I; Wiklund G; Svennerholm AM
    Vaccine; 2008 Feb; 26(6):743-52. PubMed ID: 18191006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.